Pauls Matthew

SEC Form 4 insider trading activity

Pauls Matthew has filed 7 SEC Form 4 filings (12 transaction rows) across 3 companies, including PTHS, SLNO, SVRA, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Jul 7, 2026.

On the most recent filing, Pauls Matthew is listed as Director at Pelthos Therapeutics Inc. Inside the rolling window, Pauls Matthew reported no open-market purchases and 2 open-market sales totaling $37K in PTHS. The largest disclosed transaction in the window is a sale of 786 PTHS shares on Jul 2, 2026, worth $21K.

Companies traded

Other insiders at PTHS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$37K

reported sales (SEC code S)

Companies

3

in the rolling window

Source
PTHSSale$21KJul 7SEC ↗
PTHSSale$16KApr 6SEC ↗
Showing 1–2 of 2
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Pauls Matthew made?

Pauls Matthew has filed 7 SEC Form 4 filings (12 transaction rows) across 3 companies, including PTHS, SLNO, SVRA since 2025.

Which companies does Pauls Matthew trade?

Pauls Matthew has filed SEC Form 4 disclosures for 3 companies, including PTHS, SLNO, SVRA.

When was Pauls Matthew's most recent SEC Form 4 filing?

Pauls Matthew's most recent SEC Form 4 filing on Tracefour is dated Jul 7, 2026.

What is Pauls Matthew's total buy and sell value in the current window?

Inside the rolling retention window, Pauls Matthew bought $0 and sold $37K based on SEC Form 4 filings.

What was Pauls Matthew's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 786 PTHS shares on 2026-07-02, worth $21K, per SEC Form 4 filings.